Forte Biosciences Files 8-K: Material Agreement & Equity Sales
Ticker: FBRX · Form: 8-K · Filed: Nov 20, 2024 · CIK: 1419041
Sentiment: neutral
Topics: material-agreement, equity-sale, 8-k
Related Tickers: FBRX
TL;DR
Forte Bio (FBRX) signed a big deal and sold some stock. Details in new 8-K.
AI Summary
On November 19, 2024, Forte Biosciences, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and provided a Regulation FD disclosure. The filing includes financial statements and exhibits.
Why It Matters
This 8-K filing indicates significant corporate activity, including a new material agreement and equity transactions, which could impact the company's financial structure and future operations.
Risk Assessment
Risk Level: medium — The filing details a material definitive agreement and unregistered equity sales, which can introduce financial and operational risks.
Key Players & Entities
- Forte Biosciences, Inc. (company) — Registrant
- November 19, 2024 (date) — Date of earliest event reported
- 3060 Pegasus Park Dr. Building 6 Dallas, Texas 75247 (address) — Principal Executive Offices
FAQ
What type of material definitive agreement did Forte Biosciences, Inc. enter into?
The filing states that Forte Biosciences, Inc. entered into a material definitive agreement on November 19, 2024, but the specific details of the agreement are not provided in the summary information.
What was the date of the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on November 19, 2024.
What is Forte Biosciences, Inc.'s principal executive office address?
Forte Biosciences, Inc.'s principal executive office is located at 3060 Pegasus Park Dr. Building 6, Dallas, Texas 75247.
Besides the material agreement, what other significant items are reported in this 8-K?
This 8-K filing also reports on unregistered sales of equity securities and includes a Regulation FD disclosure, along with financial statements and exhibits.
What is Forte Biosciences, Inc.'s state of incorporation and fiscal year end?
Forte Biosciences, Inc. is incorporated in Delaware and its fiscal year ends on December 31.
Filing Stats: 1,961 words · 8 min read · ~7 pages · Grade level 13.6 · Accepted 2024-11-20 16:15:29
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value FBRX The NASDAQ Stock Mar
- $5.552 — (the "Shares"), at a purchase price of $5.552 per Share, representing the average of
- $5.551 — e "Securities"), at a purchase price of $5.551 per Pre-Funded Warrant, provided that e
- $53.0 m — cement are expected to be approximately $53.0 million, before deducting offering expens
- $475,000 — ate Placement, purchasing approximately $475,000 of Securities in the aggregate. The par
Filing Documents
- d815860d8k.htm (8-K) — 40KB
- d815860dex41.htm (EX-4.1) — 69KB
- d815860dex101.htm (EX-10.1) — 226KB
- d815860dex102.htm (EX-10.2) — 99KB
- d815860dex991.htm (EX-99.1) — 10KB
- g815860g1120100400745.jpg (GRAPHIC) — 5KB
- 0001193125-24-262543.txt ( ) — 683KB
- fbrx-20241119.xsd (EX-101.SCH) — 3KB
- fbrx-20241119_lab.xml (EX-101.LAB) — 18KB
- fbrx-20241119_pre.xml (EX-101.PRE) — 11KB
- d815860d8k_htm.xml (XML) — 4KB
Forward Looking Statements
Forward Looking Statements This report contains certain forward-looking statements regarding the business of the Company that are not a description of historical facts within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the use of proceeds of the offering; the completion of the offering; and the registration of securities issued in the offering. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, those associated with market conditions; satisfaction of customary closing conditions in the Private Placement; and risks related to the Company's estimates regarding future expenses, capital requirements and need for additional financing. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included in the company's Quarterly Report on Form 10-Q filed on November 14, 2024, and elsewhere in the Company's reports and other documents that the Company has filed, or will file, with the SEC from time to time that are available at www.sec.gov. You are cautioned not to place undue reliance on forward-looking statements which are current only as of the date hereof. Except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. Item9.01.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Description 4.1 Form of Pre-Funded Warrant 10.1 Securities Purchase Agreement, dated November 19, 2024, by and among the Company and the Purchasers 10.2 Registration Rights Agreement, dated November 19, 2024, by and among the Company and the Purchasers 99.1 Press Release dated November 20, 2024 104 The cover page of this Current Report on Form 8-K, formatted in inline XBRL
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. FORTE BIOSCIENCES, INC. Date: November 20, 2024 By: /s/ Antony Riley Antony Riley Chief Financial Officer